Korea's New Fast Track Scheme A GIFT For High-Need Drugs

Nefecon, Pegcetacoplan Selected

 
• By Jung Won Shin
  
Generate a summary of this article
Listen to this article
Beta

South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.

fast track
Strategic Support On Horizon In Korea For Rapid Launch, Export Of Innovative Drugs • Source: Shutterstock

South Korea's Ministry of Food and Drug Safety (MFDS) has designated two orphan drugs - Calliditas Therapeutics AB’s budesonide and Apellis Pharmaceuticals, Inc.’s pegcetacoplan - as the second and third products to be accepted into the newly established Global Innovative Products on Fast Track (GIFT) scheme, meaning they will receive support from early-stage clinical trials to enable more rapid commercialization.

The ministry had been operating a fast track system since August 2020 amid the COVID-19 pandemic and designated 23 products...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from South Korea

Korea Revamps Drug Review Processes, Cuts Approval Timelines

 
• By Jung Won Shin

Under the new drug approval innovation measures, Korea will cut the review and approval period of new drugs to 295 days from 420 days and increase the number of expert reviewers to enhance review capabilities.

Korea’s Medical Vacuum Grows As Doctors Threaten Indefinite Walkout

 
• By Jung Won Shin

Long-running protests by South Korean doctors against government reforms, including raising medical school admissions, continue to intensify with a one-day rally by community doctors and the threat of an indefinite walkout later this month. The pharma industry is also feeling the impact on clinical trials and sales. 

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

 
• By Jung Won Shin

South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.

Major Boost For WHO-Listed Authority Scheme As US & EU Regulators Designated

 
• By Eliza Slawther

The US Food and Drug Administration and the European medicines regulatory network, which includes the European Commission, the European Medicines Agency and 30 national agencies, are now WHO-Listed Authorities under a framework launched in 2022.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By Lisa Takagi

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By Vibha Sharma

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.